Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Rachel Tyndale

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Activities & Behaviors

Physiology

Genotype

Disorders

Tobacco Use Disorder

Anatomy

Genes & Molecular Sequences

Alleles

Concepts & Ideas

Gene Frequency

Living Beings

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Bergen Andrew W; Conti David V; Van Den Berg David; Lee Wonho; Liu Jinghua; Li Dalin; Guo Nan; Mi Huaiyu; Thomas Paul D; Lessov-Schlaggar Christina N; Krasnow Ruth; He Yungang; Nishita Denise; Jiang Ruhong; McClure Jennifer B; Tildesley Elizabeth; Hops Hyman; Tyndale Rachel F; Benowitz Neal L; Lerman Caryn; Swan Gary E
Dopamine genes and nicotine dependence in treatment-seeking and community smokers.
Al Koudsi Nael; Ahluwalia Jasjit S; Lin Shih-Ku; Sellers Edward M; Tyndale Rachel F
A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo.
Thomas Paul D; Mi Huaiyu; Swan Gary E; Lerman Caryn; Benowitz Neal; Tyndale Rachel F; Bergen Andrew W; Conti David V;
A systems biology network model for genetic association studies of nicotine addiction and treatment.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Rachel Tyndale (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Bergen Andrew W; Conti David V; Van Den Berg David; Lee Wonho; Liu Jinghua; Li Dalin; Guo Nan; Mi Huaiyu; Thomas Paul D; Lessov-Schlaggar Christina N; Krasnow Ruth; He Yungang; Nishita Denise; Jiang Ruhong; McClure Jennifer B; Tildesley Elizabeth; Hops Hyman; Tyndale Rachel F; Benowitz Neal L; Lerman Caryn; Swan Gary E
Dopamine genes and nicotine dependence in treatment-seeking and community smokers.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2009;34(10):2252-64.
2009: Al Koudsi Nael; Ahluwalia Jasjit S; Lin Shih-Ku; Sellers Edward M; Tyndale Rachel F
A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo.
The pharmacogenomics journal 2009;9(4):274-82.
2009: Thomas Paul D; Mi Huaiyu; Swan Gary E; Lerman Caryn; Benowitz Neal; Tyndale Rachel F; Bergen Andrew W; Conti David V;
A systems biology network model for genetic association studies of nicotine addiction and treatment.
Pharmacogenetics and genomics 2009;19(7):538-51.
2009: Ho M K; Mwenifumbo J C; Al Koudsi N; Okuyemi K S; Ahluwalia J S; Benowitz N L; Tyndale R F
Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.
Clinical pharmacology and therapeutics 2009;85(6):635-43.
2009: Swan Gary E; Lessov-Schlaggar Christina N; Bergen Andrew W; He Yungang; Tyndale Rachel F; Benowitz Neal L
Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine.
Pharmacogenetics and genomics 2009;19(5):388-98.
2009: Yue Jiang; Khokhar Jibran; Miksys Sharon; Tyndale Rachel F
Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake.
European journal of pharmacology 2009;609(1-3):88-95.
2009: Schnoll Robert A; Patterson Freda; Wileyto E Paul; Tyndale Rachel F; Benowitz Neal; Lerman Caryn
Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study.
Pharmacology, biochemistry, and behavior 2009;92(1):6-11.
2009: Miksys Sharon; Tyndale Rachel F
Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2009;34(3):634-40.
2009: Mwenifumbo Jill C; Tyndale Rachel F
Molecular genetics of nicotine metabolism.
Handbook of experimental pharmacology 2009;(192):235-59.
2009: Ray Riju; Tyndale Rachel F; Lerman Caryn
Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes.
Journal of neurogenetics 2009;23(3):252-61.
2008: Mann Amandeep; Miksys Sharon; Lee Anna; Mash Deborah C; Tyndale Rachel F
Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment.
Neuropharmacology 2008;55(7):1147-55.
2008: Emamghoreishi Masoumeh; Bokaee Hamid-Reza; Keshavarz Mojtaba; Ghaderi Abbas; Tyndale Rachel F
CYP2A6 allele frequencies in an Iranian population.
Archives of Iranian medicine 2008;11(6):613-7.
2008: Conti David V; Lee Won; Li Dalin; Liu Jinghua; Van Den Berg David; Thomas Paul D; Bergen Andrew W; Swan Gary E; Tyndale Rachel F; Benowitz Neal L; Lerman Caryn;
Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation.
Human molecular genetics 2008;17(18):2834-48.
2008: Patterson F; Schnoll R A; Wileyto E P; Pinto A; Epstein L H; Shields P G; Hawk L W; Tyndale R F; Benowitz N; Lerman C
Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion.
Clinical pharmacology and therapeutics 2008;84(3):320-5.
2008: Mwenifumbo Jill C; Sellers Edward M; Tyndale Rachel F
Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2008;10(8):1319-25.
2008: Shram Megan J; Siu Eric C K; Li Zhaoxia; Tyndale Rachel F; Lê Anh D
Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats.
Psychopharmacology 2008;198(2):181-90.
2008: Mwenifumbo Jill C; Al Koudsi Nael; Ho Man Ki; Zhou Qian; Hoffmann Ewa B; Sellers Edward M; Tyndale Rachel F
Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent.
Human mutation 2008;29(5):679-88.
2008: Siu Eric C K; Tyndale Rachel F
Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice.
The Journal of pharmacology and experimental therapeutics 2008;324(3):992-9.
2008: Ho Man Ki; Mwenifumbo Jill C; Zhao Bin; Gillam Elizabeth M J; Tyndale Rachel F
A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent.
Pharmacogenetics and genomics 2008;18(1):67-75.
2008: Yue Jiang; Miksys Sharon; Hoffmann Ewa; Tyndale Rachel F
Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course.
Journal of psychiatry & neuroscience : JPN 2008;33(1):54-63.
2008: Mwenifumbo J C; Lessov-Schlaggar C N; Zhou Q; Krasnow R E; Swan G E; Benowitz N L; Tyndale R F
Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism.
Clinical pharmacology and therapeutics 2008;83(1):115-21.
2007: Ring Huijun Z; Valdes Ana M; Nishita Denise M; Prasad Suman; Jacob Peyton; Tyndale Rachel F; Swan Gary E; Benowitz Neal L
Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.
Pharmacogenetics and genomics 2007;17(12):1007-15.
2007: Mwenifumbo Jill C; Tyndale Rachel F
Genetic variability in CYP2A6 and the pharmacokinetics of nicotine.
Pharmacogenomics 2007;8(10):1385-402.
2007: Wall Tamara L; Schoedel Kerri; Ring Huijun Z; Luczak Susan E; Katsuyoshi Denise M; Tyndale Rachel F
Differences in pharmacogenetics of nicotine and alcohol metabolism: review and recommendations for future research.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2007;9 Suppl 3():S459-74.
2007: Lee Anna M; Jepson Christopher; Hoffmann Ewa; Epstein Leonard; Hawk Larry W; Lerman Caryn; Tyndale Rachel F
CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.
Biological psychiatry 2007;62(6):635-41.
2007: Tyndale Rachel F; Payne Jennifer I; Gerber Alexandra L; Sipe Jack C
The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2007;144B(5):660-6.
2007: Lee Anna M; Jepson Christopher; Shields Peter G; Benowitz Neal; Lerman Caryn; Tyndale Rachel F
CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(6):1312-4.
2007: Mwenifumbo Jill C; Sellers Edward M; Tyndale Rachel F
Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking.
Drug and alcohol dependence 2007;89(1):24-33.
2007: Strasser Andrew A; Malaiyandi Viba; Hoffmann Ewa; Tyndale Rachel F; Lerman Caryn
An association of CYP2A6 genotype and smoking topography.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2007;9(4):511-8.
2007: Ho M K; Tyndale R F
Overview of the pharmacogenomics of cigarette smoking.
The pharmacogenomics journal 2007;7(2):81-98.
2007: Siu Eric C K; Tyndale Rachel F
Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 mice.
Molecular pharmacology 2007;71(3):826-34.
2007: Matta Shannon G; Balfour David J; Benowitz Neal L; Boyd R Thomas; Buccafusco Jerry J; Caggiula Anthony R; Craig Caroline R; Collins Allan C; Damaj M Imad; Donny Eric C; Gardiner Phillip S; Grady Sharon R; Heberlein Ulrike; Leonard Sherry S; Levin Edward D; Lukas Ronald J; Markou Athina; Marks Michael J; McCallum Sarah E; Parameswaran Neeraja; Perkins Kenneth A; Picciotto Marina R; Quik Maryka; Rose Jed E; Rothenfluh Adrian; Schafer William R; Stolerman Ian P; Tyndale Rachel F; Wehner Jeanne M; Zirger Jeffrey M
Guidelines on nicotine dose selection for in vivo research.
Psychopharmacology 2007;190(3):269-319.
2007: Audrain-McGovern Janet; Al Koudsi Nael; Rodriguez Daniel; Wileyto E Paul; Shields Peter G; Tyndale Rachel F
The role of CYP2A6 in the emergence of nicotine dependence in adolescents.
Pediatrics 2007;119(1):e264-74.
2007: Damaj M I; Siu E C K; Sellers E M; Tyndale R F; Martin B R
Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice.
The Journal of pharmacology and experimental therapeutics 2007;320(1):250-7.
2007: Siu Eric C K; Tyndale Rachel F
Non-nicotinic therapies for smoking cessation.
Annual review of pharmacology and toxicology 2007;47():541-64.
2006: Lee Anna M; Joshi Meenal; Yue Jiang; Tyndale Rachel F
Phenobarbital induces monkey brain CYP2E1 protein but not hepatic CYP2E1, in vitro or in vivo chlorzoxazone metabolism.
European journal of pharmacology 2006;552(1-3):151-8.
2006: Benowitz Neal L; Swan Gary E; Jacob Peyton; Lessov-Schlaggar Christina N; Tyndale Rachel F
CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
Clinical pharmacology and therapeutics 2006;80(5):457-67.
2006: Malaiyandi Viba; Goodz Shari D; Sellers Edward M; Tyndale Rachel F
CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006;15(10):1812-9.
2006: Quik Maryka; Parameswaran Neeraja; McCallum Sarah E; Bordia Tanuja; Bao Shanshan; McCormack Alison; Kim Amy; Tyndale Rachel F; Langston J William; Di Monte Donato A
Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.
Journal of neurochemistry 2006;98(6):1866-75.
2006: Lee Anna M; Yue Jiang; Tyndale Rachel F
In vivo and in vitro characterization of chlorzoxazone metabolism and hepatic CYP2E1 levels in African Green monkeys: induction by chronic nicotine treatment.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(9):1508-15.
2006: Lee Anna M; Tyndale Rachel F
Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment.
Journal of psychopharmacology (Oxford, England) 2006;20(4 Suppl):7-14.
2006: Lee Anna M; Miksys Sharon; Tyndale Rachel F
Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein.
British journal of pharmacology 2006;148(6):786-94.
2006: Lerman Caryn; Tyndale Rachel; Patterson Freda; Wileyto E Paul; Shields Peter G; Pinto Angela; Benowitz Neal
Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation.
Clinical pharmacology and therapeutics 2006;79(6):600-8.
2006: Al Koudsi Nael; Mwenifumbo Jill C; Sellers Edward M; Benowitz Neal L; Swan Gary E; Tyndale Rachel F
Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics.
European journal of clinical pharmacology 2006;62(6):481-4.
2006: Karp I; O'Loughlin J; Hanley J; Tyndale R F; Paradis G
Risk factors for tobacco dependence in adolescent smokers.
Tobacco control 2006;15(3):199-204.
2006: Joshi Meenal; Tyndale Rachel F
Induction and recovery time course of rat brain CYP2E1 after nicotine treatment.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(4):647-52.
2006: Malaiyandi V; Lerman C; Benowitz N L; Jepson C; Patterson F; Tyndale R F
Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy.
Molecular psychiatry 2006;11(4):400-9.
2006: Joshi Meenal; Tyndale Rachel F
Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine.
Neuropharmacology 2006;50(5):568-75.
2006: Siu Eric C K; Wildenauer Dieter B; Tyndale Rachel F
Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5.
Psychopharmacology 2006;184(3-4):401-8.
2006: Lee Anna M; Miksys Sharon; Palmour Roberta; Tyndale Rachel F
CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment.
Neuropharmacology 2006;50(4):441-50.
2006: McCallum Sarah E; Parameswaran Neeraja; Bordia Tanuja; Fan Hong; Tyndale Rachel F; Langston J William; McIntosh J Michael; Quik Maryka
Increases in alpha4* but not alpha3*/alpha6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment.
Journal of neurochemistry 2006;96(4):1028-41.
2006: Miksys S; Tyndale R F
Nicotine induces brain CYP enzymes: relevance to Parkinson's disease.
Journal of neural transmission. Supplementum 2006;(70):177-80.
2005: Al Koudsi Nael; Tyndale Rachel F
Genetic influences on smoking: a brief review.
Therapeutic drug monitoring 2005;27(6):704-9.
2005: Miksys Sharon L; Cheung Connie; Gonzalez Frank J; Tyndale Rachel F
Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(10):1495-502.
2005: Mwenifumbo Jill C; Myers Mark G; Wall Tamara L; Lin Shih-Ku; Sellers Edward M; Tyndale Rachel F
Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method.
Pharmacogenetics and genomics 2005;15(3):189-92.
2005: Malaiyandi Viba; Sellers Edward M; Tyndale Rachel F
Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.
Clinical pharmacology and therapeutics 2005;77(3):145-58.
2005: Grabus Sheri D; Martin Billy R; Batman Angela M; Tyndale Rachel F; Sellers Edward; Damaj M Imad
Nicotine physical dependence and tolerance in the mouse following chronic oral administration.
Psychopharmacology 2005;178(2-3):183-92.
2005: Swan Gary E; Benowitz Neal L; Lessov Christina N; Jacob Peyton; Tyndale Rachel F; Wilhelmsen Kirk
Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence.
Pharmacogenetics and genomics 2005;15(2):115-25.
2004: O'Loughlin J; Paradis G; Kim W; DiFranza J; Meshefedjian G; McMillan-Davey E; Wong S; Hanley J; Tyndale R F
Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers.
Tobacco control 2004;13(4):422-8.
2004: Swan Gary E; Benowitz Neal L; Jacob Peyton; Lessov Christina N; Tyndale Rachel F; Wilhelmsen Kirk; Krasnow Ruth E; McElroy Mary R; Moore Sharyn E; Wambach Michelle
Pharmacogenetics of nicotine metabolism in twins: methods and procedures.
Twin research : the official journal of the International Society for Twin Studies 2004;7(5):435-48.
2004: McKeown-Eyssen Gail; Baines Cornelia; Cole David E C; Riley Nicole; Tyndale Rachel F; Marshall Lynn; Jazmaji Vartouhi
Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR.
International journal of epidemiology 2004;33(5):971-8.
2004: Schoedel Kerri A; Hoffmann Ewa B; Rao Yushu; Sellers Edward M; Tyndale Rachel F
Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.
Pharmacogenetics 2004;14(9):615-26.
2004: De Luca Vincenzo; Wong Albert H C; Muller Daniel J; Wong Gregory W H; Tyndale Rachel F; Kennedy James L
Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2004;29(8):1522-6.
2004: Dempsey Delia; Tutka Piotr; Jacob Peyton; Allen Faith; Schoedel Kerri; Tyndale Rachel F; Benowitz Neal L
Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.
Clinical pharmacology and therapeutics 2004;76(1):64-72.
2004: Miksys Sharon; Tyndale Rachel F
The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics.
Drug metabolism reviews 2004;36(2):313-33.
2003: Sellers Edward M; Ramamoorthy Yamini; Zeman Marilyn V; Djordjevic Mirjana V; Tyndale Rachel F
The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2003;5(6):891-9.
2003: O'Loughlin Jennifer; DiFranza Joseph; Tyndale Rachel F; Meshefedjian Garbis; McMillan-Davey Elizabeth; Clarke Paul B S; Hanley James; Paradis Gilles
Nicotine-dependence symptoms are associated with smoking frequency in adolescents.
American journal of preventive medicine 2003;25(3):219-25.
2003: Micu Alina L; Miksys Sharon; Sellers Edward M; Koop Dennis R; Tyndale Rachel F
Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism.
The Journal of pharmacology and experimental therapeutics 2003;306(3):941-7.
2003: Miksys Sharon; Lerman Caryn; Shields Peter G; Mash Deborah C; Tyndale Rachel F
Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain.
Neuropharmacology 2003;45(1):122-32.
2003: Sellers Edward M; Tyndale Rachel F; Fernandes Leona C
Decreasing smoking behaviour and risk through CYP2A6 inhibition.
Drug discovery today 2003;8(11):487-93.
2003: Howard Lisa A; Ahluwalia Jasjit S; Lin Shih-Ku; Sellers Edward M; Tyndale Rachel F
CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence.
Pharmacogenetics 2003;13(6):321-8.
2003: Zhang Wenjiang; Ramamoorthy Yamini; Tyndale Rachel F; Sellers Edward M
Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(6):768-72.
2003: Howard Lisa A; Miksys Sharon; Hoffmann Ewa; Mash Deborah; Tyndale Rachel F
Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics.
British journal of pharmacology 2003;138(7):1376-86.
2003: Gafni I; Busto U E; Tyndale R F; Kaplan H L; Sellers E M
The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo.
Journal of clinical psychopharmacology 2003;23(2):169-75.
2003: Schoedel Kerri A; Tyndale Rachel F
Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications.
Biochimica et biophysica acta 2003;1619(3):283-90.
2003: Schoedel Kerri A; Sellers Edward M; Palmour Roberta; Tyndale Rachel F
Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration.
Molecular pharmacology 2003;63(1):96-104.
2003: Tyndale Rachel F
Genetics of alcohol and tobacco use in humans.
Annals of medicine 2003;35(2):94-121.
2002: O'Loughlin J; DiFranza J; Tarasuk J; Meshefedjian G; McMillan-Davey E; Paradis G; Tyndale R F; Clarke P; Hanley J
Assessment of nicotine dependence symptoms in adolescents: a comparison of five indicators.
Tobacco control 2002;11(4):354-60.
2002: Ahijevych Karen L; Tyndale Rachel F; Dhatt Ravinder K; Weed Harrison G; Browning Kristine K
Factors influencing cotinine half-life during smoking abstinence in African American and Caucasian women.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2002;4(4):423-31.
2002: Miksys Sharon L; Tyndale Rachel F
Drug-metabolizing cytochrome P450s in the brain.
Journal of psychiatry & neuroscience : JPN 2002;27(6):406-15.
2002: Xu Chun; Goodz Shari; Sellers Edward M; Tyndale Rachel F
CYP2A6 genetic variation and potential consequences.
Advanced drug delivery reviews 2002;54(10):1245-56.
2002: Miksys Sharon; Rao Yushu; Hoffmann Ewa; Mash Deborah C; Tyndale Rachel F
Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics.
Journal of neurochemistry 2002;82(6):1376-87.
2002: Ramamoorthy Yamini; Yu Ai-ming; Suh Nina; Haining Robert L; Tyndale Rachel F; Sellers Edward M
Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.
Biochemical pharmacology 2002;63(12):2111-9.
2002: Zhang Wenjiang; Ramamoorthy Yamini; Tyndale Rachel F; Glick Stanley D; Maisonneuve Isabelle M; Kuehne Martin E; Sellers Edward M
Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(6):663-9.
2002: Pritzker David; Kanungo Anish; Kilicarslan Tansel; Tyndale Rachel F; Sellers Edward M
Designer drugs that are potent inhibitors of CYP2D6.
Journal of clinical psychopharmacology 2002;22(3):330-2.
2002: Fernandes Leona C; Kilicarslan Tansel; Kaplan Howard L; Tyndale Rachel F; Sellers Edward M; Romach Myroslava K
Treatment of codeine dependence with inhibitors of cytochrome P450 2D6.
Journal of clinical psychopharmacology 2002;22(3):326-9.
2002: Howard Lisa A; Sellers Edward M; Tyndale Rachel F
The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence.
Pharmacogenomics 2002;3(2):185-99.
2002: Zhang Wenjiang; Ramamoorthy Yamini; Kilicarslan Tansel; Nolte Helma; Tyndale Rachel F; Sellers Edward M
Inhibition of cytochromes P450 by antifungal imidazole derivatives.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(3):314-8.
2002: Tyndale Rachel F; Sellers Edward M
Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior.
Therapeutic drug monitoring 2002;24(1):163-71.
2002: Xu C; Rao Y S; Xu B; Hoffmann E; Jones J; Sellers E M; Tyndale R F
An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles.
Biochemical and biophysical research communications 2002;290(1):318-24.
2002: Goodz Shari D; Tyndale Rachel F
Genotyping human CYP2A6 variants.
Methods in enzymology 2002;357():59-69.
2001: Howard L A; Micu A L; Sellers E M; Tyndale R F
Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver.
The Journal of pharmacology and experimental therapeutics 2001;299(2):542-50.
2001: Schoedel K A; Sellers E M; Tyndale R F
Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain.
Biochemical pharmacology 2001;62(8):1025-36.
2001: Ramamoorthy Y; Tyndale R F; Sellers E M
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.
Pharmacogenetics 2001;11(6):477-87.
2001: Zhang W; Kilicarslan T; Tyndale R F; Sellers E M
Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(6):897-902.
2001: Kilicarslan T; Haining R L; Rettie A E; Busto U; Tyndale R F; Sellers E M
Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(4 Pt 1):460-5.
2001: Wong J M; Harper P A; Meyer U A; Bock K W; Morike K; Lagueux J; Ayotte P; Tyndale R F; Sellers E M; Manchester D K; Okey A B
Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro.
Pharmacogenetics 2001;11(1):85-94.
2000: Rao Y; Hoffmann E; Zia M; Bodin L; Zeman M; Sellers E M; Tyndale R F
Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking.
Molecular pharmacology 2000;58(4):747-55.
2000: Kathiramalainathan K; Kaplan H L; Romach M K; Busto U E; Li N Y; Säwe J; Tyndale R F; Sellers E M
Inhibition of cytochrome P450 2D6 modifies codeine abuse liability.
Journal of clinical psychopharmacology 2000;20(4):435-44.
2000: Sellers E M; Kaplan H L; Tyndale R F
Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking.
Clinical pharmacology and therapeutics 2000;68(1):35-43.
2000: Miksys S; Rao Y; Sellers E M; Kwan M; Mendis D; Tyndale R F
Regional and cellular distribution of CYP2D subfamily members in rat brain.
Xenobiotica; the fate of foreign compounds in biological systems 2000;30(6):547-64.
2000: Miksys S; Hoffmann E; Tyndale R F
Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment.
Biochemical pharmacology 2000;59(12):1501-11.
2000: Romach M K; Otton S V; Somer G; Tyndale R F; Sellers E M
Cytochrome P450 2D6 and treatment of codeine dependence.
Journal of clinical psychopharmacology 2000;20(1):43-5.
2000: Sellers E M; Tyndale R F
Mimicking gene defects to treat drug dependence.
Annals of the New York Academy of Sciences 2000;909():233-46.
1999: Tyndale R F; Li Y; Li N Y; Messina E; Miksys S; Sellers E M
Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(8):924-30.
1998: Nowak M P; Sellers E M; Tyndale R F
Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies.
Clinical pharmacology and therapeutics 1998;64(4):378-83.
1998: Droll K; Bruce-Mensah K; Otton S V; Gaedigk A; Sellers E M; Tyndale R F
Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.
Pharmacogenetics 1998;8(4):325-33.
1998: Zawertailo L A; Kaplan H L; Busto U E; Tyndale R F; Sellers E M
Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study.
Journal of clinical psychopharmacology 1998;18(4):332-7.
1997: Tyndale R F; Bhave S V; Hoffmann E; Hoffmann P L; Tabakoff B; Tobin A J; Olsen R W
Pentobarbital decreases the gamma-aminobutyric acidA receptor subunit gamma-2 long/short mRNA ratio by a mechanism distinct from receptor occupation.
The Journal of pharmacology and experimental therapeutics 1997;283(1):350-7.
1997: Messina E S; Tyndale R F; Sellers E M
A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.
The Journal of pharmacology and experimental therapeutics 1997;282(3):1608-14.
1997: Nowak M P; Tyndale R F; Sellers E M
CYP2D6 phenotype and genotype in a Canadian Native Indian population.
Pharmacogenetics 1997;7(2):145-8.
1997: Cheung S; Nolte H; Otton S V; Tyndale R F; Wu P H; Sellers E M
Simultaneous gas chromatographic determination of methamphetamine, amphetamine and their p-hydroxylated metabolites in plasma and urine.
Journal of chromatography. B, Biomedical sciences and applications 1997;690(1-2):77-87.
1997: Tomkins D M; Otton S V; Joharchi N; Li N Y; Balster R F; Tyndale R F; Sellers E M
Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats.
The Journal of pharmacology and experimental therapeutics 1997;280(3):1374-82.
1997: Sellers E M; Otton S V; Tyndale R F
The potential role of the cytochrome P-450 2D6 pharmacogenetic polymorphism in drug abuse.
NIDA research monograph 1997;173():6-26.
1996: Charles A C; Kodali S K; Tyndale R F
Intercellular calcium waves in neurons.
Molecular and cellular neurosciences 1996;7(5):337-53.
1995: Beischlag T V; Marchese A; Meador-Woodruff J H; Damask S P; O'Dowd B F; Tyndale R F; van Tol H H; Seeman P; Niznik H B
The human dopamine D5 receptor gene: cloning and characterization of the 5'-flanking and promoter region.
Biochemistry 1995;34(17):5960-70.
1995: Greger V; Knoll J H; Woolf E; Glatt K; Tyndale R F; DeLorey T M; Olsen R W; Tobin A J; Sikela J M; Nakatsu Y
The gamma-aminobutyric acid receptor gamma 3 subunit gene (GABRG3) is tightly linked to the alpha 5 subunit gene (GABRA5) on human chromosome 15q11-q13 and is transcribed in the same orientation.
Genomics 1995;26(2):258-64.
1994: Hales T G; Tyndale R F
Few cell lines with GABAA mRNAs have functional receptors.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1994;14(9):5429-36.
1994: Tyndale R F; Hales T G; Olsen R W; Tobin A J
Distinctive patterns of GABAA receptor subunit mRNAs in 13 cell lines.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1994;14(9):5417-28.
1993: Nakatsu Y; Tyndale R F; DeLorey T M; Durham-Pierre D; Gardner J M; McDanel H J; Nguyen Q; Wagstaff J; Lalande M; Sikela J M
A cluster of three GABAA receptor subunit genes is deleted in a neurological mutant of the mouse p locus.
Nature 1993;364(6436):448-50.
1992: Otton S V; Tyndale R F; Wu D; Inaba T; Kalow W; Sellers E M
Catalytic and immunologic similarities between monkey and human liver cytochrome P-450db1 (human cytochrome P-450 2D6).
Drug metabolism and disposition: the biological fate of chemicals 1992;20(1):1-5.
1991: Tyndale R; Aoyama T; Broly F; Matsunaga T; Inaba T; Kalow W; Gelboin H V; Meyer U A; Gonzalez F J
Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.
Pharmacogenetics 1991;1(1):26-32.
1991: Tyndale R F; Sunahara R; Inaba T; Kalow W; Gonzalez F J; Niznik H B
Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6.
Molecular pharmacology 1991;40(1):63-8.
1991: Tyndale R F; Kalow W; Inaba T
Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).
British journal of clinical pharmacology 1991;31(6):655-60.
1990: Tyndale R F; Gonzalez F J; Hardwick J P; Kalow W; Inaba T
Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry.
Pharmacology & toxicology 1990;67(1):14-8.
1990: Tyndale R F; Inaba T
Simultaneous determination of haloperidol and reduced haloperidol by gas chromatography using a megabore column with electron-capture detection: application to microsomal oxidation of reduced haloperidol.
Journal of chromatography 1990;529(1):182-8.
1990: Niznik H B; Tyndale R F; Sallee F R; Gonzalez F J; Hardwick J P; Inaba T; Kalow W
The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins.
Archives of biochemistry and biophysics 1990;276(2):424-32.
1989: Tyndale R F; Inaba T; Kalow W
Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro.
Drug metabolism and disposition: the biological fate of chemicals 1989;17(3):334-40.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Rachel Tyndale

Research Profile (preview)

Chemicals & Drugs

Activities & Behaviors

Physiology

Disorders

Anatomy

Genes & Molecular Sequences

Concepts & Ideas

Living Beings

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Rachel Tyndale (preview)

All Publications